The biotech CEO job after the Series A
With David Crean, PhD, MBA, managing partner at Cardiff Advisory
In this Spotify episode, we cover the skills that a CEO needs to learn post-Series A.
Now


For nearly 15 years, I have advised senior leadership in life sciences – at the World Bank, Oxfam, IBM Life Sciences, and Accenture Strategy. In every role, the work has been the same: helping biopharma executives make consequential decisions on capital allocation, M&A, restructuring, technology strategy, and market access.
My background is an unusual mix. I trained as a physician in Moscow, then in health economics at the London School of Hygiene and Tropical Medicine as a Melinda Gates Scholar, and I have advised at the level of national economic policy. Most of my work now is closer to the operating problems companies actually face: raising and allocating capital, structuring transactions and partnerships across borders, and building the operating discipline that turns funded strategy into working companies. I live in San Diego.
Read the full biography$35B+
In biopharma transactions advised, on the buy side and the sell side
$1B
Restructuring led end to end: P&L, workforce, and operating model
$125M+
In capital raised for healthcare and life sciences
$130M
HIV vaccine program managed end to end across research, funding, and delivery partners
Transaction and post-merger integration advisory.
Let me know if this resonates with you.
I speak and write on AI in drug development, biotech dealmaking, and the economics of pharma.
With David Crean, PhD, MBA, managing partner at Cardiff Advisory
In this Spotify episode, we cover the skills that a CEO needs to learn post-Series A.
I also host Off-Label, a podcast in which biopharma executives debate the industry’s hardest problems.
Julien helped to build our R&D roadmap and market analysis across teams on two continents, ready to be presented to our board. You do not need to manage him.
He possesses two critical traits: non-intuitive thinking and skill in high-pressure negotiations. He is a very confident and ruthless operator.
Dr. Willard is uncompromising in his strategic focus. He is rare, a physician who understands both the science and the boardroom.
Julien is a perfectionist. He is no yes-man; expect pushback, grounded in data and research.
One of the few advisors I have worked with who connects global supply chain, corporate strategy, and digital into a single point of view. He earns the room.
He is able to range in his thinking from high-level systems analysis and business planning to very specific implementation challenges.
I work with biopharma leadership ready to win at all costs: on transactions, on growth, on the hard operational decisions that separate companies that scale from those that stall.